Navigation Links
Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann 'Hot Topics in Therapeutics' Roundtable Conference
Date:2/7/2011

EAST NORRITON, Pa., Feb. 7, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 2:00 p.m. EST.  Dr. Nichtberger will also participate in a panel discussion titled "IPO Window-Creaking Open or Wide Open?" the following day on Tuesday, February 15, 2011, at 1:30 p.m. EST.  


Dr. Nichtberger will also be presenting at the upcoming Leerink Swann "Hot Topics in Therapeutics" Roundtable Conference on Wednesday, February 16, 2011, at 9:35 a.m. EST.  Dr. Nichtberger will also participate in the Emerging Platforms panel discussion at 10:45 a.m. EST that same day.  


Replays of both webcasts will be available in the Investors section of the Company's at www.tengion.com.  Investors interested in listening to any live webcast are advised to log on before the start time in order to download any required software.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
2. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
3. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
4. Tengion Appoints A. Brian Davis Chief Financial Officer
5. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
6. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
7. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
8. Tengion Announces Second Closing of Series C Financing
9. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Celtic Pharma Announces Presentation of Preclinical Data at the 69th Annual Meeting of the AAD in New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... research is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets ... convened more than 100 clinical trial leaders from over 40 sponsor, CRO and site ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and ... a vendor-supported, portable online UHPLC, with robust, probe-based sampling. , Online ...
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... today that the Company has concluded an agreement with ... for a 90-day period to acquire units of the ... approximately USD 3.7 million.  Concurrently with ... Tamarack under which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
Breaking Biology Technology:
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
Breaking Biology News(10 mins):